Literature DB >> 3440100

Disposition of antipyrine in African patients with Hodgkin's lymphoma.

F D Juma1.   

Abstract

The pharmacokinetics of antipyrine were studied in 12 healthy volunteers and 10 patients of Kenya African origin with Hodgkin's lymphoma. The half-life of antipyrine was 12.2 +/- 1.3 h (mean + s.d.), while the apparent volume of distribution (V) was 0.67 +/- 0.11 l kg-1 (mean +/- s.d.) and the total body clearance was 40.7 +/- 3.2 ml kg-1 h-1 (mean +/- s.d.) in the healthy volunteers. The antipyrine half-life in the patients with advanced Hodgkin's lymphoma was 17.1 +/- 2.7 h (mean +/- s.d.). The apparent volume of distribution was 0.72 +/- 0.14 l kg-1 (mean +/- s.d.) which was larger than in healthy volunteers (P less than 0.05). The total body clearance was 30.3 +/- 9.4 ml kg-1 h-1 (mean + s.d.) and this was reduced compared with that in healthy volunteers (P less than 0.02). After cytotoxic therapy the half-life in the patients with advanced Hodgkin's lymphoma was significantly decreased to 8.3 +/- 1.3 h (mean +/- s.d.) (P less than 0.07), and the apparent volume of distribution was reduced to 0.65 +/- 0.07 l kg-1 (mean +/- s.d.) (P less than 0.05) while the total body clearance increased to 52.8 +/- 5.5 ml kg-1 h-1 (mean +/- s.d.) (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3440100      PMCID: PMC1386407          DOI: 10.1111/j.1365-2125.1987.tb03249.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  The fate of antipyrine in man.

Authors:  B B BRODIE; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1950-01       Impact factor: 4.030

2.  The biotransformation of cyclophosphamide in man: influence of prednisone.

Authors:  O K Faber; H T Mouridsen; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-09

3.  Metabolism of drugs. LXX. Further study on antipyrine metabolism.

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1971-01       Impact factor: 1.645

4.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

5.  Decreased half life of cyclophosphamide in patients under continual treatment.

Authors:  M D'Incalci; G Bolis; T Facchinetti; C Mangioni; L Morasca; P Morazzoni; M Salmona
Journal:  Eur J Cancer       Date:  1979-01       Impact factor: 9.162

6.  Rapid gas-liquid chromatographic estimation of antipyrine in plasma.

Authors:  L F Prescott; K K Adjepon-Yamoah; E Roberts
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

7.  Factors affecting antipyrine metabolism in West African villagers.

Authors:  H S Fraser; C J Bulpitt; C Kahn; G Mould; J C Mucklow; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

8.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.